AOA Dx

"The first half of 2024 has brought positive momentum to women’s health: from President Biden’s Executive Order on Advancing Women’s Health Research and Innovation to Vice President Harris' support of women's reproductive health and safety, from the launch of a women’s health PAC to Melinda French Gates’ planned investment of $1B in women, including their health." Some key highlights: ✅ Increased VC Funding: Women’s health companies received $679.48M in venture capital funding in the first half of 2024, a 3% increase from the previous high in mid-2022. ✅Rising Average Deal Size: The average deal size for women’s health companies has reached a new high of $12.58M in the first half of 2024. ✅Growing Number of Large Deals: The number of women’s health companies raising over $50M in a single round has increased, with at least four companies achieving this in the first half of 2024. ✅Stable Percentage of Total VC Funding: Women’s health has maintained a steady share of overall VC funding in healthcare, receiving about 2.5% in the first half of 2024, slightly above the historical average. Interesting and informative read by Eva Epker! Check out the full article here:

Thank you Dr. Elizabeth Garner for your invaluable support!

Ovarian cancer can progress rapidly, advancing from early stages to more advanced forms within a year. Women need access to earlier and more accurate detection for ovarian cancer. 👏

Attention Colorado community! If you're interested in making an impact on women's health, check out the work we are doing with the Women's Health PAC! It's time the women's health becomes a national priority. Learn more about how we are working towards this goal:

It's time that women have access to a test that will effectively detect ovarian cancer in the early stages. 👏 "The CA-125 blood test, which is often done together with a transvaginal ultrasound, may be used to try to detect ovarian cancer early, especially in women with an increased risk of the disease. Although this test can help to diagnose ovarian cancer in women who have symptoms and can be used to evaluate the recurrence of cancer in women previously diagnosed with the disease, it has not been shown to be an effective ovarian cancer screening test." At AOA Dx, we're at the forefront of innovating the field of glycolipids through the utilization of tumor marker gangliosides, the next class of biomarkers in early cancer detection. We need better options for ovarian cancer patients, this isn't a want, it's a need.

We are so proud to share we have been accepted to the Hewlett Packard Enterprise Diversity Startup program and the Alpha3 Cloud Startup program! We look forward to sharing more updates and participating in this leading program!

The AOA team had a busy week! Between some friendly team competition and attending the incredible American Cancer Society Fork for Cancer event, it was a week to remember. We may have some laser tag and bowling pros on the team! Can you guess who? 👏 Charles M. Nichols, Ph.D. Mattie Goldberg Anna Milik Jeter Vuna Fa Abigail McElhinny Lindsey Kemp Michael Matthews Megan D. Miller-Awe, M.S. Rachel C. Adam Cadwallader Robert Law, Ph.D. Connor Hansen Mark Sianipar Enkhtuya Radnaa

"Results of a recent study found that individuals with endometriosis may be at an increased risk for ovarian cancer. Those with ovarian endometriomas, deep infiltrating endometriosis, or both were at the highest level of risk for ovarian cancer." TLDR: ✅ Endometriosis is a complex condition that involves uterine-like tissue growing in other areas outside the uterus. ✅ Researchers are interested in understanding how endometriosis relates to risk for other conditions, including cancer. ✅ Individuals experiencing endometriosis and those potentially at risk for ovarian cancer can seek proper guidance and follow up with specialists. "Currently, there is no reliable method recommended to screen for any type of ovarian cancer. With the advent and growth of understanding about molecular mechanisms underlying the disease, this will hopefully change soon. However, the more there is a family history of cancer it is prudent to consider genetic counseling and appropriate testing.” <--At AOA Dx, we're working to bring a new reality to women globally. Women NEED a reliable method to screen for any type of ovarian cancer. We can no longer go on without one.

We could not be more excited to share that ovarian cancer thriver, Jess Jata and her husband, welcomed their twin boys into the world, thanks to their amazing surrogate! Jess, who battled Stage 3C ovarian cancer, just received her lowest CA125 results post-diagnosis yesterday. Many of you may remember Jess from our "Not So Silent" campaign, where we had the privilege of sharing her inspiring journey. Congratulations, Jess! We wish you all the best as you embark on this wonderful new chapter of your life! 💕

Women should have the power to make rapid and educated decisions about their health. Early detection is crucial in achieving this. Join us as we revolutionize early detection for ovarian cancer patients!